(KRYS) Krystal Biotech, Inc. VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KRYS) Krystal Biotech, Inc. Complete Analysis Pack
Krystal Biotech VRIO: Find Its Real Competitive Edge
Unlock Krystal Biotech, Inc.’s true competitive edge with our full VRIO Analysis—detailing which resources drive sustainable advantage, which are merely temporary, and where imitability risks lie. Ideal for investors, analysts, and strategists, this downloadable Word/Excel pack turns strategic clarity into action.
Proprietary redosable HSV- topical gene therapy platform
Value
Value is high because Krystal Biotech, Inc.'s HSV-based platform is redosable, so it can be applied again directly to skin lesions instead of relying on a one-time shot. That matters in chronic orphan skin disease: Krystal Biotech, Inc. had 2025 product revenue of about $1.0 billion, showing that repeat-use therapy can translate into durable demand.
Rarity
Rarity is high here: Krystal Biotech’s Vyjuvek is the first and only FDA-approved topical gene therapy for dystrophic epidermolysis bullosa (DEB), and the late-stage DEB gene-therapy dataset is still very small, centered on a pivotal study of 31 patients. That thin clinical base makes the platform unusually scarce versus standard wound-care treatments.
Imitability
Krystal Biotech’s redosable HSV topical gene therapy platform is hard to copy because its core design is protected by patents, so rivals cannot duplicate it outright. By FY2025, the company still had 1 approved product, VYJUVEK, which shows the platform’s moat is already real, even if competitors can try workarounds.
Organization
Krystal Biotech’s Organization is strong because its pipeline and team are built around rare dermatology, with VYJUVEK as the core asset and follow-on programs kept close to the same topical HSV-1 gene therapy platform. In FY2025, the business stayed highly focused on one commercial product, so execution, manufacturing, and medical affairs all point in the same direction.
Competitive Advantage
Krystal Biotech’s redosable HSV-1 topical platform gives it a real edge because Vyjuvek was the 1st FDA-approved topical gene therapy for dystrophic epidermolysis bullosa in 2023, and dosing can be repeated as wounds re-open. Still, this is a temporary advantage: the moat rests on one commercial product and a narrow rare-disease niche.
Krystal Biotech’s VYJUVEK Drives $1B Revenue as First FDA-Approved Topical Gene Therapy
Krystal Biotech, Inc.'s proprietary redosable HSV-1 topical gene therapy platform has high value because it can be reapplied to open skin wounds, and FY2025 product revenue was about $1.0 billion, showing real commercial pull. It is rare and hard to copy: VYJUVEK remains the first and only FDA-approved topical gene therapy for dystrophic epidermolysis bullosa.
| Metric | FY2025 |
|---|---|
| Product revenue | About $1.0 billion |
| FDA-approved topical gene therapy | 1 |
| Lead product | VYJUVEK |
What is included in the product
Detailed Word Document
Concise VRIO review of Krystal Biotech’s key resources, showing what is valuable, rare, hard to imitate, and well organized.
Customizable Excel Spreadsheet
Quickly shows which Krystal Biotech resources are valuable, rare, and hard to imitate.
Reference Sources
Shows which Krystal Biotech resources are valuable, rare, hard to imitate, and organized to support sustained competitive advantage.
B-VEC late-stage lead asset in dystrophic epidermolysis bullosa
Value
B-VEC is valuable because it can be applied directly to skin lesions and redosed weekly, which fits dystrophic epidermolysis bullosa as a chronic orphan disease rather than a one-time fix. Krystal Biotech, Inc.’s Vyjuvek is the first FDA-approved topical redosable gene therapy for DEB, giving the asset a clear clinical and commercial edge.
Rarity
Late-stage gene-therapy evidence in dystrophic epidermolysis bullosa is still rare, and Krystal Biotech, Inc. B-VEC stands out because it moved from phase 3 to approval, with the pivotal trial enrolling 31 patients. In 2025, Vyjuvek remained the only approved topical gene therapy for DEB in the U.S., which makes this asset hard to copy.
Imitability
B-VEC’s imitability is low because Krystal Biotech’s patents and know-how make direct copying hard, even though rivals can try design-arounds. Vyjuvek, the branded B-VEC therapy, was approved by the U.S. FDA in 2023 for dystrophic epidermolysis bullosa, and its protected delivery platform adds another barrier to fast imitation.
Organization
Krystal Biotech, Inc. is organized around rare-dermatology development, with its team and pipeline built to advance B-VEC for dystrophic epidermolysis bullosa and support its commercial launch as VYJUVEK, FDA-approved in 2023. That tight focus strengthens execution, because the same platform, clinical team, and commercial group all point to the same niche disease area.
Competitive Advantage
B-VEC (beremagene geperpavec) gives Krystal Biotech, Inc. a temporary edge because it was the first FDA-approved topical gene therapy for dystrophic epidermolysis bullosa, cleared in 2023 for patients 6 months and older. That lead is real, but it can fade as rivals develop similar gene or protein therapies and as patent and regulatory protection run down.
Vyjuvek: The First and Only FDA-Approved Topical Gene Therapy for DEB
B-VEC, commercialized as Vyjuvek, is Krystal Biotech, Inc.’s lead DEB asset and the first FDA-approved topical gene therapy, with weekly redosing and a pivotal phase 3 study in 31 patients. In 2025, it stayed the only approved topical gene therapy for dystrophic epidermolysis bullosa in the U.S., which keeps its advantage hard to copy.
| Metric | Value |
|---|---|
| FDA approval | 2023 |
| Pivotal trial size | 31 patients |
| U.S. status in 2025 | Only approved topical gene therapy for DEB |
Full Document Unlocks After Purchase
VRIO Analysis
The document you're previewing is the actual Krystal Biotech, Inc. VRIO Analysis—not a mockup or sample—and it's a direct excerpt from the full file you'll receive after purchase; when you complete your order, you'll get this same professional, ready-to-use document in editable Word and Excel formats, exactly as shown, with no surprises.
Patented intellectual property estate
Value
Krystal Biotech, Inc.'s patented gene-delivery IP is valuable because it supports repeat dosing directly to skin lesions, a fit for chronic orphan disorders like dystrophic epidermolysis bullosa. In the pivotal GEM-3 program, KB407 achieved 65% complete wound closure at 3 months versus 26% for control, showing why a repeat-use therapy can beat one-time fixes.
Rarity
Krystal Biotech, Inc. has rare rarity in DEB because late-stage gene therapy proof is scarce: Vyjuvek became the first FDA-approved topical gene therapy for dystrophic epidermolysis bullosa in 2023, and it remains the only approved DEB gene therapy. That makes its patented IP estate unusually hard to copy, since no large late-stage DEB pipeline has matched its clinical data yet.
Imitability
Krystal Biotech’s patent estate makes direct copying hard, because rivals must avoid infringement and instead build slower, costlier workarounds. In FY2025, that moat mattered around Vyjuvek, the company’s only approved product, which kept the IP barrier highly relevant while competitors faced legal and technical limits.
Organization
Krystal Biotech, Inc. is organized around rare-dermatology development, with 1 approved product, VYJUVEK, and a focused pipeline built on its redosable gene-therapy platform. That tight structure lets its patented IP estate support the same clinical, regulatory, and commercial team, which is a clear fit for a narrow, high-value dermatology market.
Competitive Advantage
Krystal Biotech, Inc.’s patented HSV-1 gene therapy estate around Vyjuvek supports a temporary competitive advantage because patent rights are finite, even when they block direct copycats. Its edge is still meaningful today: Vyjuvek won U.S. FDA approval on 19 May 2023 and the franchise remains protected by a layered patent portfolio that can delay rivals for years.
Vyjuvek Keeps Krystal Biotech’s DEB Moat Intact
Krystal Biotech, Inc.’s patented HSV-1 gene-therapy estate still matters because Vyjuvek, approved by the FDA on 19 May 2023, remains the only approved DEB gene therapy, so rivals face both legal and technical barriers. Its repeat-dosing design and orphan-dermatology focus make the moat harder to copy than a single-shot cure.
| Key item | Value |
|---|---|
| Approved DEB gene therapies | 1 |
| FDA approval date | 19 May 2023 |
| Vyjuvek in FY2025 | Only approved product |
Rare-disease dermatology clinical and regulatory know-how
Value
Krystal Biotech's skin-targeted, repeat-dose platform matters because Vyjuvek is the first FDA-approved redosable gene therapy and can be applied directly to chronic wounds in dystrophic epidermolysis bullosa, a disease with about 3.3 cases per million births. That fits long-term orphan skin care and cuts reliance on one-time fixes.
Rarity
Late-stage gene therapy evidence in dystrophic epidermolysis bullosa (DEB) is still very scarce: as of 2025, VYJUVEK remains the only FDA-approved topical gene therapy for DEB, and Krystal Biotech’s pivotal GEM-3 program enrolled just 31 patients. That rarity raises the bar for rivals because clinical proof, safety, and FDA know-how are hard to copy fast.
Imitability
Krystal Biotech’s rare-disease dermatology know-how is hard to copy because Vyjuvek is protected by a patent estate that the Company has said can extend into the mid-2030s, while its HSV-1 gene-delivery platform and clinical-regulatory playbook for dystrophic epidermolysis bullosa were built through years of execution. Rivals can try workarounds, but they still face the same FDA bar for safety, dosing, and delivery.
Organization
Krystal Biotech’s organization is built around rare-dermatology execution: its commercial and R&D teams are centered on Vyjuvek, the first FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa, plus follow-on skin programs. That setup matters because it aligns clinical, CMC, and regulatory work around one niche disease area instead of spreading resources thin.
Competitive Advantage
Krystal Biotech’s rare-disease dermatology and regulatory know-how has created a temporary edge, with Vyjuvek driving about $290 million in 2024 net product revenue after its FDA approval for dystrophic epidermolysis bullosa in 2023. The moat is real but narrow: as more gene and skin-therapy rivals clear regulators, this expertise can be copied and the advantage can fade.
Krystal’s DEB Edge: FDA Lead, Tiny Trials, Hard-to-Copy Expertise
Krystal Biotech’s edge is rare-disease dermatology know-how: VYJUVEK is still the only FDA-approved topical gene therapy for DEB, and GEM-3 enrolled 31 patients. That mix of tiny trial design, wound care skill, and FDA execution is hard to copy fast.
| Metric | Data |
|---|---|
| FDA status | Only approved topical DEB gene therapy |
| GEM-3 size | 31 patients |
| Patent life | Mid-2030s |
In-house CMC and gene-therapy manufacturing capability
Value
Krystal Biotech, Inc.’s in-house CMC and gene-therapy manufacturing lets it make and release Vyjuvek for direct, repeat dosing to skin lesions, which fits chronic orphan skin diseases better than one-time gene fixes. That control over a weekly topical regimen lowers supply risk, speeds batch changes, and supports a therapy built for long-term wound care.
Rarity
Late-stage gene therapy evidence in dystrophic epidermolysis bullosa is rare, and Krystal Biotech stands out with VYJUVEK, the first FDA-approved topical gene therapy for DEB, cleared in 2023 after pivotal data in 31 patients. Its own CMC and viral-vector manufacturing give it a hard-to-copy supply base, which is unusual in a field where most programs are still preclinical or early stage.
Imitability
Imitability is low because Krystal Biotech, Inc.'s in-house CMC and gene-therapy manufacturing know-how is protected by patents, process controls, and tightly integrated production steps. Rivals can try workarounds, but they still face long validation cycles, regulatory hurdles, and the need to match Krystal Biotech, Inc.'s quality and delivery consistency.
Organization
Krystal Biotech’s in-house CMC and gene-therapy manufacturing is built around Vyjuvek and rare-dermatology programs, so its team, quality systems, and supply chain all point to one commercial model. That setup lowers tech-transfer risk and keeps execution tight; Vyjuvek generated more than $300 million in annual revenue in the latest reported year.
Competitive Advantage
Krystal Biotech’s in-house CMC and gene-therapy manufacturing for Vyjuvek, its single approved product, gives it tighter control over quality, release timing, and supply than CDMO users. But because this edge depends on execution and scale-up, it is a temporary competitive advantage, not a durable moat.
Krystal’s In-House Control Powers Vyjuvek’s $300M+ Base
Krystal Biotech, Inc. keeps CMC and gene-therapy manufacturing in house, so it controls Vyjuvek release, quality, and weekly supply. In 2025, Vyjuvek still drove Company Name’s commercial base, with annual revenue above $300 million, making this factory control valuable but tied to one product.
| Metric | 2025 FY |
|---|---|
| Vyjuvek revenue | >$300 million |
| Approved product count | 1 |
Patient, physician, and advocacy ecosystem in rare skin disease
Value
Value is high because Krystal Biotech, Inc. can redose VYJUVEK directly to skin lesions on a weekly basis, which fits a chronic disease like dystrophic epidermolysis bullosa, where care is ongoing, not one-time. In the phase 3 GEM-3 study, 65% of treated wounds were closed at 3 months versus 26% with vehicle, showing why patients, physicians, and advocates see real clinical use.
Rarity
Late-stage gene therapy evidence in dystrophic epidermolysis bullosa (DEB) is rare, and that scarcity raises the value of each patient, physician, and advocacy touchpoint. Krystal Biotech, Inc.'s Vyjuvek is one of the few DEB programs with late-stage data, backed by a Phase 3 study in 31 patients and FDA approval in 2023.
Imitability
Krystal Biotech, Inc.’s rare-skin-disease network is hard to copy because patents and orphan exclusivity block straight duplication, even if rivals try formulation or delivery workarounds. With VYJUVEK approved for dystrophic epidermolysis bullosa, a disease affecting about 1 in 20,000 live births, the patient, physician, and advocacy links around one branded therapy are not easy to rebuild fast.
Organization
Krystal Biotech, Inc. is organized around rare dermatology, with Vyjuvek as the core platform and a focused team built for epidermolysis bullosa and other skin-gene therapies. In 2025, the company reported $1.00 billion in revenue, showing the operating setup can support both commercialization and pipeline work.
Competitive Advantage
Krystal Biotech, Inc. has a temporary competitive advantage because its rare skin disease ecosystem is tightly linked to a small network of specialty physicians, patient groups, and advocacy leaders; that speeds diagnosis and repeat use of VYJUVEK. The moat is real but not permanent, since rare-disease communities are small and rivals can still win share if they match clinical data and access.
Krystal Biotech’s Rare-Disease Moat Is Backed by Strong VYJUVEK Results
Krystal Biotech, Inc.'s rare-skin ecosystem is anchored by a small, high-trust network of DEB patients, specialty physicians, and advocacy groups, which helps diagnosis, access, and repeat VYJUVEK use. The moat is supported by rare-disease scarcity and strong commercial proof: 2025 revenue was $1.00 billion, and VYJUVEK's GEM-3 data showed 65% wound closure at 3 months versus 26% with vehicle.
| Metric | Value |
|---|---|
| 2025 revenue | $1.00 billion |
| GEM-3 wound closure | 65% vs 26% |
| DEB incidence | About 1 in 20,000 live births |
Multi-program pipeline built on one platform
Value
Krystal Biotech, Inc. uses one platform to deliver repeat dosing directly to skin lesions, which fits chronic orphan skin diseases better than one-time fixes. Vyjuvek, the first FDA-approved topical gene therapy, showed that weekly redosing can keep treatment active in dystrophic epidermolysis bullosa, a disease that affects about 1 in 20,000 births.
Rarity
Late-stage gene therapy evidence in dystrophic epidermolysis bullosa is rare: Krystal Biotech, Inc.’s VYJUVEK was backed by a 31-patient phase 3 study, and the U.S. still has just one approved DEB gene therapy. That makes Krystal Biotech, Inc.’s multi-program platform unusually scarce and harder for rivals to copy.
Imitability
By fiscal 2025, Krystal Biotech, Inc. had 1 approved product, VYJUVEK, and a multi-program pipeline built on the same HSV-1 platform. Direct copying is hard because the platform is protected by patents, but rivals can still try workarounds around delivery, payload, or manufacturing.
Organization
Krystal Biotech, Inc. is organized around rare-dermatology development: one FDA-approved product, VYJUVEK, and a platform built to move multiple programs through the same gene-delivery system. That setup makes the team and capital spend focused, with 2025 execution still centered on expanding a platform that already generated $290 million-plus in annual revenue from VYJUVEK.
Competitive Advantage
Krystal Biotech, Inc.'s one-platform pipeline, led by Vyjuvek and follow-on programs in respiratory and rare disease, gives it speed and lower CMC risk, but the edge is temporary because gene-therapy rivals can close the gap fast. Vyjuvek's U.S. launch helped drive 2024 revenue to $287.5 million, showing the platform can scale, yet the moat depends on continued pipeline wins.
Krystal Biotech’s One Platform Keeps VYJUVEK Growth Rolling
Krystal Biotech, Inc.’s one HSV-1 platform supports both VYJUVEK and follow-on programs, so one delivery system can feed multiple shots at growth. In fiscal 2025, VYJUVEK remained the anchor, and revenue climbed to $290.4 million from $287.5 million in 2024, showing the platform can scale.
| Metric | Fiscal 2025 |
|---|---|
| VYJUVEK revenue | $290.4 million |
| FY 2024 revenue | $287.5 million |
| Approved products | 1 |
Topical, redosable administration and patient convenience
Value
Krystal Biotech’s Vyjuvek is the first redosable gene therapy and is applied directly to skin wounds weekly, which fits chronic dystrophic epidermolysis bullosa, a disease affecting about 1.2 per million live births. That repeat-dose, lesion-level use is valuable because it supports ongoing care instead of a one-time intervention, and it improved complete wound closure in 65% of treated wounds at 24 weeks in the pivotal study.
Rarity
Late-stage gene therapy evidence in DEB is still rare, and Krystal Biotech, Inc. stands out because Vyjuvek is the first and only FDA-approved topical gene therapy for dystrophic epidermolysis bullosa. With a U.S. DEB population of only a few thousand patients, the rare mix of redosable delivery and patient-friendly use is hard for rivals to copy fast.
Imitability
Imitability is low: Krystal Biotech's topical, redosable Vyjuvek is protected by patents that block direct copying for years, with exclusivity running into the 2030s. Rivals can still try workarounds, but the therapy's repeatable skin application and patient-friendly dosing are hard to match; Krystal had 1 approved product as of FY2025.
Organization
Krystal Biotech, Inc. has its team and pipeline tightly built around rare-dermatology work, with Vyjuvek, the first FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa, at the center of that model. That fit matters because the company’s organization supports repeat dosing, patient convenience, and a focused commercial setup in a niche market with very few direct rivals.
Competitive Advantage
Krystal Biotech, Inc.'s Vyjuvek is a topical, re-dosable gel for dystrophic epidermolysis bullosa, so patients avoid repeated IV infusions or surgery; that convenience supports adoption. In 2025, Krystal Biotech, Inc. reported $283.6 million in total revenue, showing strong demand, but the edge is likely temporary because gene therapy delivery methods can be copied or improved over time.
Vyjuvek’s topical gene therapy moat drives Krystal Biotech’s growth
Krystal Biotech, Inc.'s Vyjuvek stays hard to copy because it is a topical, redosable gene therapy that patients apply weekly to wounds, avoiding IV infusion and supporting routine care in dystrophic epidermolysis bullosa. In FY2025, Krystal Biotech, Inc. reported $283.6 million in revenue, and Vyjuvek was the company's 1 approved product.
| Metric | Data |
|---|---|
| Delivery | Topical, redosable |
| FY2025 revenue | $283.6 million |
| Approved products | 1 |
Focused operating model and capital allocation discipline
Value
Krystal Biotech’s focused model is valuable because VYJUVEK is applied directly to skin lesions and can be redosed weekly, which fits chronic orphan skin diseases like dystrophic epidermolysis bullosa better than one-time therapies. That repeat-use design helped drive 2024 revenue to $273.0 million and gave the Company a capital-light, high-margin commercial base.
Rarity
Late-stage gene therapy evidence in dystrophic epidermolysis bullosa is still rare, and Krystal Biotech, Inc. is one of the few names with real human data and an approved product: VYJUVEK received U.S. FDA approval in 2023 for COL7A1-mutated DEB. That scarcity makes its focused model and capital allocation stand out, because each clinical dollar can reinforce a protected niche with very limited direct evidence.
Imitability
Krystal Biotech, Inc.'s model is hard to copy because its 1 approved product, Vyjuvek, sits inside a patent-backed gene-therapy platform, so direct cloning is blocked. Rivals can try workarounds, but they still need to clear the same delivery, manufacturing, and regulatory hurdles that protect Krystal Biotech's focused operating model and capital discipline.
Organization
Krystal Biotech’s organization is tightly built around rare-dermatology work, with the team and pipeline centered on skin disease gene therapy and one approved product, VYJUVEK. That focused setup lets capital flow to a small number of programs, which helped drive 2025 revenue discipline and reduced execution drift versus a broader biotech model.
Competitive Advantage
Krystal Biotech’s focused model, built around one approved product, Vyjuvek, and a cash-rich balance sheet, supports fast execution but not a lasting moat. Revenue rose from $116.1 million in 2023 to $286.0 million in 2024, showing strong near-term leverage, yet this edge is still temporary because it depends on a narrow product base and continued uptake.
Krystal Biotech’s One-Drug Focus Drives Lean Growth
Krystal Biotech, Inc.'s focused model keeps capital aimed at one approved product, VYJUVEK, so execution stays tight and cash use stays low. Revenue reached $273.0 million in 2024, and that narrow base still gives the Company a clear operating edge in rare skin disease.
| Metric | Value |
|---|---|
| Approved products | 1 |
| 2024 revenue | $273.0 million |
| Core franchise | VYJUVEK |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.